William Steinbach
Concepts (503)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Aspergillus fumigatus | 54 | 2021 | 101 | 20.770 |
Why?
| Antifungal Agents | 90 | 2023 | 339 | 15.210 |
Why?
| Fungal Proteins | 30 | 2021 | 124 | 10.410 |
Why?
| Aspergillosis | 48 | 2020 | 125 | 9.810 |
Why?
| Calcineurin | 28 | 2022 | 71 | 9.080 |
Why?
| Echinocandins | 35 | 2017 | 64 | 5.270 |
Why?
| Hyphae | 17 | 2018 | 32 | 5.190 |
Why?
| Mycoses | 28 | 2023 | 158 | 4.680 |
Why?
| Cell Wall | 17 | 2020 | 56 | 3.630 |
Why?
| HSP90 Heat-Shock Proteins | 10 | 2016 | 50 | 3.540 |
Why?
| Lipopeptides | 29 | 2017 | 63 | 2.750 |
Why?
| Tacrolimus | 15 | 2022 | 51 | 2.640 |
Why?
| Candidiasis | 23 | 2022 | 114 | 2.640 |
Why?
| Fungi | 11 | 2016 | 44 | 2.610 |
Why?
| Gene Expression Regulation, Fungal | 12 | 2019 | 55 | 2.570 |
Why?
| Aspergillus | 15 | 2017 | 52 | 2.540 |
Why?
| Drug Resistance, Fungal | 14 | 2023 | 31 | 2.480 |
Why?
| Septins | 5 | 2017 | 19 | 2.450 |
Why?
| Hematopoietic Stem Cell Transplantation | 18 | 2023 | 553 | 2.320 |
Why?
| Tacrolimus Binding Protein 1A | 7 | 2022 | 14 | 2.290 |
Why?
| Candidiasis, Invasive | 5 | 2023 | 6 | 2.220 |
Why?
| Candida | 14 | 2022 | 60 | 2.100 |
Why?
| Spores, Fungal | 7 | 2018 | 21 | 2.000 |
Why?
| Cyclic AMP-Dependent Protein Kinases | 3 | 2020 | 51 | 1.890 |
Why?
| beta-Glucans | 9 | 2022 | 23 | 1.860 |
Why?
| Cryptococcus neoformans | 6 | 2023 | 27 | 1.810 |
Why?
| Pediatrics | 7 | 2018 | 277 | 1.730 |
Why?
| Peptides, Cyclic | 14 | 2007 | 41 | 1.730 |
Why?
| Child | 56 | 2023 | 6824 | 1.560 |
Why?
| Invasive Pulmonary Aspergillosis | 5 | 2017 | 12 | 1.550 |
Why?
| Mannans | 6 | 2017 | 16 | 1.510 |
Why?
| Triazoles | 16 | 2021 | 107 | 1.510 |
Why?
| Humans | 142 | 2023 | 49827 | 1.490 |
Why?
| Virulence | 11 | 2020 | 171 | 1.430 |
Why?
| Mucormycosis | 5 | 2021 | 29 | 1.380 |
Why?
| Phosphorylation | 8 | 2020 | 536 | 1.370 |
Why?
| Fungemia | 8 | 2015 | 37 | 1.370 |
Why?
| Myosin Type V | 2 | 2020 | 5 | 1.350 |
Why?
| Microbial Sensitivity Tests | 15 | 2023 | 271 | 1.290 |
Why?
| Mutation | 10 | 2020 | 1293 | 1.220 |
Why?
| Chitin Synthase | 3 | 2011 | 6 | 1.140 |
Why?
| Protein Processing, Post-Translational | 4 | 2017 | 171 | 1.110 |
Why?
| Immunocompromised Host | 11 | 2020 | 120 | 1.100 |
Why?
| Opportunistic Infections | 6 | 2017 | 59 | 1.060 |
Why?
| Child, Preschool | 31 | 2021 | 3853 | 1.010 |
Why?
| Calcium | 4 | 2019 | 397 | 0.960 |
Why?
| Azoles | 7 | 2020 | 28 | 0.940 |
Why?
| Stress, Physiological | 6 | 2019 | 170 | 0.940 |
Why?
| Adolescent | 35 | 2022 | 6340 | 0.930 |
Why?
| Animals | 32 | 2023 | 13150 | 0.930 |
Why?
| Protein Multimerization | 3 | 2020 | 49 | 0.930 |
Why?
| Gene Expression Regulation, Enzymologic | 2 | 2017 | 181 | 0.880 |
Why?
| Amphotericin B | 12 | 2023 | 110 | 0.870 |
Why?
| Mice | 18 | 2023 | 5720 | 0.870 |
Why?
| Amino Acid Sequence | 11 | 2021 | 587 | 0.860 |
Why?
| Pyrimidines | 11 | 2011 | 191 | 0.820 |
Why?
| Chitin | 3 | 2011 | 6 | 0.810 |
Why?
| Candida albicans | 7 | 2019 | 31 | 0.810 |
Why?
| Proteome | 2 | 2020 | 173 | 0.790 |
Why?
| Virus Diseases | 2 | 2019 | 40 | 0.790 |
Why?
| Prodrugs | 1 | 2021 | 32 | 0.780 |
Why?
| ras Proteins | 2 | 2012 | 64 | 0.770 |
Why?
| Respiratory Tract Infections | 2 | 2019 | 75 | 0.770 |
Why?
| Infant | 27 | 2021 | 3551 | 0.770 |
Why?
| DNA, Fungal | 3 | 2017 | 43 | 0.750 |
Why?
| COP-Coated Vesicles | 1 | 2020 | 6 | 0.730 |
Why?
| Catalytic Domain | 3 | 2017 | 57 | 0.710 |
Why?
| Cyclosporine | 8 | 2017 | 64 | 0.690 |
Why?
| Morphogenesis | 2 | 2012 | 16 | 0.690 |
Why?
| Male | 46 | 2020 | 25093 | 0.680 |
Why?
| Drug Discovery | 2 | 2019 | 85 | 0.680 |
Why?
| Neoplasms | 9 | 2020 | 1233 | 0.670 |
Why?
| Actins | 3 | 2018 | 118 | 0.660 |
Why?
| Disease Models, Animal | 8 | 2017 | 1451 | 0.660 |
Why?
| Antigens, Fungal | 3 | 2022 | 24 | 0.650 |
Why?
| Training Support | 1 | 2018 | 11 | 0.650 |
Why?
| Protein Binding | 5 | 2020 | 660 | 0.650 |
Why?
| Organ Transplantation | 5 | 2020 | 46 | 0.640 |
Why?
| Gene Deletion | 6 | 2017 | 266 | 0.640 |
Why?
| Practice Guidelines as Topic | 3 | 2017 | 448 | 0.620 |
Why?
| Ribosomal Proteins | 1 | 2017 | 25 | 0.600 |
Why?
| Fellowships and Scholarships | 1 | 2018 | 111 | 0.590 |
Why?
| Molecular Sequence Data | 8 | 2016 | 797 | 0.590 |
Why?
| Protein Interaction Maps | 1 | 2017 | 23 | 0.580 |
Why?
| Signal Transduction | 8 | 2016 | 1617 | 0.580 |
Why?
| Infant, Newborn | 21 | 2020 | 2744 | 0.570 |
Why?
| Immunosuppressive Agents | 6 | 2022 | 220 | 0.570 |
Why?
| Aminoglycosides | 5 | 2010 | 21 | 0.560 |
Why?
| Myosins | 1 | 2016 | 17 | 0.550 |
Why?
| Hospitalization | 3 | 2019 | 653 | 0.540 |
Why?
| Protein Transport | 5 | 2018 | 179 | 0.530 |
Why?
| Prospective Studies | 10 | 2022 | 2344 | 0.520 |
Why?
| Galactose | 6 | 2017 | 28 | 0.520 |
Why?
| Transcription Factors | 4 | 2019 | 563 | 0.520 |
Why?
| HSP70 Heat-Shock Proteins | 1 | 2015 | 62 | 0.500 |
Why?
| Molecular Chaperones | 1 | 2015 | 64 | 0.500 |
Why?
| Microscopy, Fluorescence | 4 | 2020 | 162 | 0.490 |
Why?
| Cell Division | 1 | 2015 | 292 | 0.480 |
Why?
| Sepsis | 2 | 2015 | 220 | 0.480 |
Why?
| Enzyme Inhibitors | 2 | 2015 | 391 | 0.480 |
Why?
| Drug Therapy, Combination | 8 | 2012 | 378 | 0.480 |
Why?
| Models, Biological | 2 | 2018 | 728 | 0.480 |
Why?
| Promoter Regions, Genetic | 2 | 2013 | 477 | 0.470 |
Why?
| Otitis Media | 3 | 2003 | 29 | 0.460 |
Why?
| Pathology, Molecular | 1 | 2013 | 22 | 0.460 |
Why?
| Scedosporium | 2 | 2003 | 4 | 0.460 |
Why?
| Sensitivity and Specificity | 7 | 2022 | 854 | 0.450 |
Why?
| United States | 13 | 2023 | 4838 | 0.440 |
Why?
| Transcriptional Activation | 1 | 2013 | 122 | 0.440 |
Why?
| Lysine | 1 | 2014 | 90 | 0.440 |
Why?
| Treatment Outcome | 15 | 2023 | 5138 | 0.440 |
Why?
| Lipoproteins | 4 | 2005 | 39 | 0.430 |
Why?
| Tubulin | 1 | 2013 | 22 | 0.430 |
Why?
| Genes, Fungal | 3 | 2010 | 35 | 0.430 |
Why?
| Internship and Residency | 3 | 2004 | 446 | 0.430 |
Why?
| Risk Factors | 14 | 2023 | 3619 | 0.410 |
Why?
| Drug Delivery Systems | 1 | 2013 | 136 | 0.410 |
Why?
| Cell Membrane | 4 | 2017 | 248 | 0.400 |
Why?
| Lung | 6 | 2016 | 480 | 0.390 |
Why?
| Clostridium Infections | 2 | 2023 | 55 | 0.390 |
Why?
| Cell Polarity | 1 | 2011 | 16 | 0.380 |
Why?
| Neutropenia | 4 | 2020 | 117 | 0.370 |
Why?
| Female | 28 | 2020 | 26329 | 0.370 |
Why?
| Pulmonary Surfactant-Associated Protein D | 1 | 2010 | 1 | 0.370 |
Why?
| Peptides | 4 | 2004 | 222 | 0.370 |
Why?
| Microbial Viability | 3 | 2016 | 30 | 0.360 |
Why?
| Drug Therapy | 1 | 2010 | 46 | 0.360 |
Why?
| Green Fluorescent Proteins | 3 | 2017 | 90 | 0.360 |
Why?
| Candidemia | 2 | 2023 | 5 | 0.360 |
Why?
| Cations | 1 | 2010 | 10 | 0.360 |
Why?
| Calcium-Transporting ATPases | 1 | 2010 | 14 | 0.360 |
Why?
| Amino Acid Motifs | 3 | 2016 | 56 | 0.350 |
Why?
| Protein Structure, Tertiary | 4 | 2015 | 253 | 0.350 |
Why?
| Peptide Synthases | 2 | 2006 | 4 | 0.350 |
Why?
| Clinical Trials as Topic | 6 | 2015 | 460 | 0.340 |
Why?
| Mutant Proteins | 2 | 2020 | 37 | 0.330 |
Why?
| Biguanides | 2 | 2011 | 2 | 0.330 |
Why?
| Cross Infection | 3 | 2017 | 95 | 0.330 |
Why?
| Golgi Apparatus | 2 | 2010 | 99 | 0.330 |
Why?
| Genes, ras | 1 | 2008 | 43 | 0.330 |
Why?
| Homeostasis | 1 | 2010 | 199 | 0.320 |
Why?
| Lung Diseases, Fungal | 2 | 2008 | 31 | 0.320 |
Why?
| Anti-Bacterial Agents | 7 | 2020 | 743 | 0.320 |
Why?
| Chromatography, Liquid | 3 | 2017 | 232 | 0.320 |
Why?
| Mutagenesis, Site-Directed | 2 | 2019 | 99 | 0.310 |
Why?
| Sequence Deletion | 3 | 2018 | 67 | 0.300 |
Why?
| Meningitis, Cryptococcal | 1 | 2007 | 10 | 0.300 |
Why?
| Models, Molecular | 3 | 2017 | 337 | 0.300 |
Why?
| Otolaryngology | 3 | 2004 | 55 | 0.300 |
Why?
| Binding Sites | 2 | 2019 | 377 | 0.300 |
Why?
| Evolution, Molecular | 1 | 2008 | 99 | 0.300 |
Why?
| Endocarditis | 2 | 2004 | 32 | 0.290 |
Why?
| Polyenes | 2 | 2023 | 4 | 0.290 |
Why?
| Polymerase Chain Reaction | 3 | 2017 | 455 | 0.290 |
Why?
| Gliotoxin | 1 | 2006 | 1 | 0.280 |
Why?
| Lepidoptera | 2 | 2017 | 4 | 0.280 |
Why?
| Proteomics | 2 | 2020 | 328 | 0.270 |
Why?
| Biopsy | 2 | 2020 | 582 | 0.270 |
Why?
| Tandem Mass Spectrometry | 2 | 2017 | 236 | 0.260 |
Why?
| Conserved Sequence | 2 | 2018 | 56 | 0.260 |
Why?
| Incidence | 5 | 2018 | 1003 | 0.260 |
Why?
| Protein Subunits | 2 | 2018 | 77 | 0.250 |
Why?
| Microtubules | 2 | 2018 | 41 | 0.250 |
Why?
| Time Factors | 6 | 2023 | 2912 | 0.250 |
Why?
| Otitis Media with Effusion | 2 | 2004 | 15 | 0.250 |
Why?
| Antibiotic Prophylaxis | 3 | 2020 | 62 | 0.240 |
Why?
| Mitosporic Fungi | 1 | 2004 | 2 | 0.240 |
Why?
| Otoscopy | 1 | 2004 | 4 | 0.240 |
Why?
| Mycology | 1 | 2003 | 2 | 0.230 |
Why?
| Adult | 17 | 2023 | 13160 | 0.230 |
Why?
| Medical Laboratory Personnel | 1 | 2003 | 4 | 0.230 |
Why?
| Mycetoma | 1 | 2003 | 1 | 0.230 |
Why?
| Sterols | 1 | 2023 | 8 | 0.230 |
Why?
| Pulmonary Aspergillosis | 3 | 2015 | 5 | 0.230 |
Why?
| Clinical Competence | 2 | 2004 | 398 | 0.220 |
Why?
| Education, Medical, Continuing | 1 | 2003 | 68 | 0.220 |
Why?
| Bacteremia | 2 | 2020 | 92 | 0.220 |
Why?
| Communicable Diseases, Emerging | 1 | 2003 | 11 | 0.220 |
Why?
| Inflammatory Bowel Diseases | 1 | 2023 | 53 | 0.220 |
Why?
| Egtazic Acid | 2 | 2015 | 16 | 0.220 |
Why?
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2020 | 91 | 0.220 |
Why?
| Lactams, Macrocyclic | 2 | 2012 | 14 | 0.210 |
Why?
| Benzoquinones | 2 | 2012 | 29 | 0.210 |
Why?
| Ergosterol | 2 | 2023 | 10 | 0.210 |
Why?
| Stem Cell Transplantation | 1 | 2004 | 181 | 0.210 |
Why?
| Mucorales | 2 | 2020 | 11 | 0.210 |
Why?
| Models, Statistical | 1 | 2004 | 225 | 0.210 |
Why?
| Sequence Alignment | 3 | 2021 | 121 | 0.210 |
Why?
| Colony Count, Microbial | 2 | 2016 | 65 | 0.210 |
Why?
| Education, Medical | 1 | 2003 | 112 | 0.200 |
Why?
| Dose-Response Relationship, Drug | 4 | 2020 | 1374 | 0.200 |
Why?
| Mucor | 1 | 2021 | 8 | 0.200 |
Why?
| Educational Measurement | 1 | 2004 | 210 | 0.200 |
Why?
| Osteomyelitis | 1 | 2003 | 126 | 0.200 |
Why?
| Gene Expression | 2 | 2017 | 608 | 0.200 |
Why?
| Isoxazoles | 1 | 2021 | 14 | 0.200 |
Why?
| Cryptococcosis | 2 | 2019 | 20 | 0.190 |
Why?
| Adrenal Cortex Hormones | 2 | 2018 | 93 | 0.190 |
Why?
| Bacteriological Techniques | 1 | 2001 | 41 | 0.190 |
Why?
| Adenoviridae Infections | 1 | 2020 | 2 | 0.190 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2017 | 63 | 0.190 |
Why?
| Dwarfism | 1 | 2000 | 4 | 0.190 |
Why?
| Tomography, X-Ray Computed | 2 | 2020 | 1159 | 0.190 |
Why?
| Debridement | 1 | 2020 | 45 | 0.190 |
Why?
| Bone Marrow Transplantation | 1 | 2001 | 116 | 0.190 |
Why?
| Lupus Erythematosus, Systemic | 1 | 2001 | 70 | 0.190 |
Why?
| Cardiomegaly | 1 | 2000 | 34 | 0.180 |
Why?
| Retrospective Studies | 8 | 2020 | 6117 | 0.180 |
Why?
| Transcription, Genetic | 2 | 2012 | 371 | 0.180 |
Why?
| Phenotype | 2 | 2018 | 727 | 0.180 |
Why?
| Drug Resistance, Microbial | 4 | 2007 | 46 | 0.180 |
Why?
| Bacterial Infections | 1 | 2001 | 98 | 0.180 |
Why?
| Salvage Therapy | 1 | 2020 | 139 | 0.180 |
Why?
| Deafness | 1 | 2000 | 31 | 0.180 |
Why?
| Protein Structure, Secondary | 1 | 2020 | 72 | 0.180 |
Why?
| Sequence Homology, Amino Acid | 2 | 2018 | 146 | 0.180 |
Why?
| Cells, Cultured | 2 | 2023 | 1571 | 0.180 |
Why?
| Coccidioides | 1 | 2019 | 3 | 0.170 |
Why?
| Mice, Inbred A | 1 | 2019 | 15 | 0.170 |
Why?
| Biological Transport | 1 | 2020 | 173 | 0.170 |
Why?
| Kaplan-Meier Estimate | 2 | 2012 | 469 | 0.170 |
Why?
| Cohort Studies | 6 | 2023 | 1422 | 0.170 |
Why?
| Molecular Dynamics Simulation | 1 | 2019 | 33 | 0.170 |
Why?
| Cytochrome P-450 Enzyme System | 1 | 2020 | 195 | 0.170 |
Why?
| Active Transport, Cell Nucleus | 1 | 2019 | 34 | 0.170 |
Why?
| Crystallography, X-Ray | 1 | 2019 | 147 | 0.170 |
Why?
| Kidney | 1 | 2023 | 665 | 0.170 |
Why?
| Survival Rate | 4 | 2018 | 905 | 0.170 |
Why?
| International Cooperation | 2 | 2012 | 44 | 0.170 |
Why?
| Cord Blood Stem Cell Transplantation | 1 | 2018 | 5 | 0.170 |
Why?
| Calcium Signaling | 1 | 2019 | 56 | 0.170 |
Why?
| Computer Simulation | 1 | 2020 | 282 | 0.160 |
Why?
| Abnormalities, Multiple | 1 | 2000 | 167 | 0.160 |
Why?
| Curriculum | 1 | 2002 | 404 | 0.160 |
Why?
| Drug Interactions | 3 | 2010 | 206 | 0.160 |
Why?
| National Institutes of Health (U.S.) | 1 | 2018 | 46 | 0.160 |
Why?
| Luminescent Proteins | 1 | 2018 | 53 | 0.160 |
Why?
| Insulin Resistance | 1 | 2000 | 264 | 0.160 |
Why?
| Respiratory Therapy | 1 | 2018 | 34 | 0.160 |
Why?
| Leukemia, Myeloid, Acute | 3 | 2020 | 183 | 0.150 |
Why?
| Molecular Sequence Annotation | 1 | 2017 | 27 | 0.150 |
Why?
| Drug Synergism | 3 | 2011 | 150 | 0.150 |
Why?
| Immunoprecipitation | 1 | 2017 | 59 | 0.150 |
Why?
| Glucosyltransferases | 1 | 2017 | 6 | 0.150 |
Why?
| Acetylation | 1 | 2018 | 99 | 0.150 |
Why?
| Antibodies, Fungal | 1 | 2017 | 4 | 0.150 |
Why?
| Intensive Care Units, Pediatric | 2 | 2017 | 168 | 0.150 |
Why?
| Consensus Development Conferences as Topic | 1 | 2017 | 12 | 0.150 |
Why?
| Genes, Reporter | 1 | 2017 | 89 | 0.150 |
Why?
| Immunoassay | 1 | 2017 | 20 | 0.150 |
Why?
| Inpatients | 1 | 2019 | 189 | 0.150 |
Why?
| Protein Interaction Mapping | 1 | 2017 | 40 | 0.150 |
Why?
| Mass Spectrometry | 1 | 2019 | 306 | 0.150 |
Why?
| Blood Proteins | 1 | 2017 | 82 | 0.150 |
Why?
| Myeloid Cells | 1 | 2017 | 39 | 0.150 |
Why?
| Logistic Models | 4 | 2023 | 891 | 0.150 |
Why?
| Registries | 2 | 2012 | 518 | 0.150 |
Why?
| Diabetes Mellitus | 1 | 2000 | 283 | 0.140 |
Why?
| Age Factors | 4 | 2018 | 1090 | 0.140 |
Why?
| Structure-Activity Relationship | 1 | 2018 | 394 | 0.140 |
Why?
| Escherichia coli | 1 | 2017 | 186 | 0.140 |
Why?
| DNA Mutational Analysis | 1 | 2017 | 175 | 0.140 |
Why?
| Protein Conformation | 1 | 2017 | 166 | 0.140 |
Why?
| Candida glabrata | 1 | 2016 | 3 | 0.140 |
Why?
| Phylogeny | 2 | 2015 | 230 | 0.140 |
Why?
| Cyclophilin A | 1 | 2016 | 2 | 0.140 |
Why?
| Gene Knockout Techniques | 1 | 2016 | 40 | 0.140 |
Why?
| Moths | 1 | 2015 | 4 | 0.130 |
Why?
| Middle Aged | 9 | 2012 | 11997 | 0.130 |
Why?
| Substrate Specificity | 1 | 2016 | 195 | 0.130 |
Why?
| Flucytosine | 2 | 2005 | 14 | 0.130 |
Why?
| Drug Tolerance | 1 | 2015 | 60 | 0.130 |
Why?
| Biomedical Research | 1 | 2018 | 231 | 0.130 |
Why?
| Heat-Shock Response | 1 | 2015 | 28 | 0.130 |
Why?
| Bronchoalveolar Lavage | 1 | 2015 | 9 | 0.130 |
Why?
| Safety | 2 | 2005 | 78 | 0.120 |
Why?
| Intracellular Space | 1 | 2014 | 25 | 0.120 |
Why?
| Decision Support Techniques | 1 | 2015 | 70 | 0.120 |
Why?
| Hematologic Neoplasms | 2 | 2017 | 99 | 0.120 |
Why?
| Chemistry, Pharmaceutical | 2 | 2005 | 32 | 0.120 |
Why?
| Databases, Factual | 3 | 2007 | 664 | 0.120 |
Why?
| Aged | 8 | 2012 | 9272 | 0.120 |
Why?
| Randomized Controlled Trials as Topic | 3 | 2022 | 553 | 0.120 |
Why?
| Mice, Inbred C57BL | 1 | 2019 | 1806 | 0.120 |
Why?
| Lung Diseases | 1 | 2015 | 93 | 0.120 |
Why?
| Virulence Factors | 2 | 2022 | 78 | 0.110 |
Why?
| Patient Selection | 3 | 2020 | 251 | 0.110 |
Why?
| Acoustic Impedance Tests | 2 | 2004 | 8 | 0.110 |
Why?
| Graft vs Host Disease | 3 | 2018 | 74 | 0.110 |
Why?
| Drug Design | 2 | 2021 | 120 | 0.110 |
Why?
| Drug Resistance, Multiple, Fungal | 1 | 2012 | 2 | 0.110 |
Why?
| Transplantation, Homologous | 2 | 2020 | 138 | 0.110 |
Why?
| Epidemiologic Studies | 1 | 2012 | 25 | 0.110 |
Why?
| Europe | 1 | 2012 | 74 | 0.110 |
Why?
| Carrier Proteins | 1 | 2014 | 304 | 0.110 |
Why?
| Culture Media | 2 | 2010 | 93 | 0.110 |
Why?
| Lipoylation | 1 | 2012 | 3 | 0.110 |
Why?
| Serine C-Palmitoyltransferase | 1 | 2012 | 6 | 0.100 |
Why?
| Cytosol | 1 | 2012 | 82 | 0.100 |
Why?
| Palmitates | 1 | 2012 | 29 | 0.100 |
Why?
| Infant, Premature, Diseases | 2 | 2017 | 94 | 0.100 |
Why?
| Corneal Ulcer | 1 | 2011 | 4 | 0.100 |
Why?
| Fever | 1 | 2012 | 117 | 0.100 |
Why?
| Eye Infections, Fungal | 1 | 2011 | 19 | 0.100 |
Why?
| Cytoplasm | 1 | 2011 | 90 | 0.100 |
Why?
| Drug Dosage Calculations | 1 | 2011 | 10 | 0.100 |
Why?
| Cell Shape | 1 | 2011 | 20 | 0.100 |
Why?
| Metabolic Clearance Rate | 1 | 2011 | 68 | 0.100 |
Why?
| Acute Disease | 2 | 2002 | 369 | 0.090 |
Why?
| Glycoside Hydrolases | 1 | 2010 | 17 | 0.090 |
Why?
| Immunologic Deficiency Syndromes | 2 | 2017 | 20 | 0.090 |
Why?
| Cell Proliferation | 2 | 2017 | 1007 | 0.090 |
Why?
| Young Adult | 5 | 2022 | 3936 | 0.090 |
Why?
| Cricetulus | 1 | 2010 | 97 | 0.090 |
Why?
| Sorbitol | 1 | 2010 | 5 | 0.090 |
Why?
| CHO Cells | 1 | 2010 | 120 | 0.090 |
Why?
| Cricetinae | 1 | 2010 | 192 | 0.090 |
Why?
| Saline Solution, Hypertonic | 1 | 2010 | 15 | 0.090 |
Why?
| Hydrogen-Ion Concentration | 1 | 2010 | 174 | 0.090 |
Why?
| DNA Primers | 1 | 2010 | 206 | 0.090 |
Why?
| Administration, Oral | 2 | 2021 | 423 | 0.090 |
Why?
| Mice, Inbred Strains | 1 | 2010 | 161 | 0.090 |
Why?
| Fluconazole | 2 | 2009 | 34 | 0.090 |
Why?
| Genome, Fungal | 2 | 2006 | 38 | 0.080 |
Why?
| Aged, 80 and over | 3 | 2023 | 3125 | 0.080 |
Why?
| Fatal Outcome | 3 | 2004 | 195 | 0.080 |
Why?
| Disinfectants | 2 | 2011 | 12 | 0.080 |
Why?
| Esophageal Diseases | 1 | 2009 | 21 | 0.080 |
Why?
| Base Sequence | 1 | 2010 | 650 | 0.080 |
Why?
| Drug Approval | 2 | 2006 | 47 | 0.080 |
Why?
| Intensive Care Units, Neonatal | 3 | 2005 | 110 | 0.080 |
Why?
| Glucose | 1 | 2010 | 340 | 0.080 |
Why?
| Zinc Fingers | 1 | 2008 | 23 | 0.080 |
Why?
| Fluorescent Dyes | 1 | 2008 | 101 | 0.080 |
Why?
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2008 | 2 | 0.080 |
Why?
| Up-Regulation | 1 | 2010 | 450 | 0.080 |
Why?
| Coronary Disease | 1 | 1988 | 132 | 0.070 |
Why?
| Flow Cytometry | 1 | 2010 | 470 | 0.070 |
Why?
| Microbiological Techniques | 1 | 2007 | 8 | 0.070 |
Why?
| Trans-Activators | 1 | 2008 | 134 | 0.070 |
Why?
| Predictive Value of Tests | 2 | 2007 | 904 | 0.070 |
Why?
| Meningitis, Bacterial | 1 | 2006 | 6 | 0.070 |
Why?
| Professional Misconduct | 1 | 2006 | 6 | 0.070 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 245 | 0.070 |
Why?
| Infectious Disease Medicine | 2 | 2016 | 5 | 0.070 |
Why?
| Neuroaspergillosis | 1 | 2006 | 1 | 0.070 |
Why?
| Mice, Inbred ICR | 1 | 2006 | 21 | 0.070 |
Why?
| Blood-Borne Pathogens | 1 | 2006 | 7 | 0.070 |
Why?
| Saccharomyces cerevisiae Proteins | 1 | 2008 | 155 | 0.070 |
Why?
| Cell Degranulation | 1 | 2006 | 4 | 0.070 |
Why?
| Animals, Outbred Strains | 1 | 2006 | 11 | 0.070 |
Why?
| Mice, Inbred DBA | 1 | 2006 | 45 | 0.070 |
Why?
| Ethics, Research | 1 | 2006 | 39 | 0.070 |
Why?
| Multigene Family | 1 | 2006 | 56 | 0.070 |
Why?
| Proportional Hazards Models | 2 | 2004 | 406 | 0.070 |
Why?
| Mast Cells | 1 | 2006 | 52 | 0.070 |
Why?
| Regression Analysis | 2 | 2004 | 395 | 0.070 |
Why?
| Radiography | 2 | 1985 | 489 | 0.070 |
Why?
| Costs and Cost Analysis | 1 | 2006 | 95 | 0.070 |
Why?
| Itraconazole | 1 | 2005 | 40 | 0.060 |
Why?
| Societies, Medical | 2 | 2016 | 175 | 0.060 |
Why?
| Thiazoles | 1 | 2005 | 51 | 0.060 |
Why?
| Multivariate Analysis | 3 | 2019 | 585 | 0.060 |
Why?
| DNA-Binding Proteins | 1 | 2008 | 436 | 0.060 |
Why?
| Internet | 1 | 2007 | 261 | 0.060 |
Why?
| Radiographic Image Enhancement | 2 | 1984 | 30 | 0.060 |
Why?
| Down-Regulation | 1 | 2006 | 349 | 0.060 |
Why?
| Radiation Dosage | 2 | 1983 | 157 | 0.060 |
Why?
| Candidiasis, Chronic Mucocutaneous | 1 | 2004 | 2 | 0.060 |
Why?
| Candida tropicalis | 1 | 2004 | 2 | 0.060 |
Why?
| Case-Control Studies | 2 | 2020 | 1128 | 0.060 |
Why?
| Administration, Inhalation | 1 | 2004 | 107 | 0.060 |
Why?
| Mice, Inbred BALB C | 2 | 2017 | 303 | 0.060 |
Why?
| Serial Passage | 1 | 2023 | 3 | 0.060 |
Why?
| Granulocytes | 1 | 2003 | 27 | 0.060 |
Why?
| Meninges | 1 | 2003 | 13 | 0.060 |
Why?
| Ascomycota | 1 | 2003 | 9 | 0.060 |
Why?
| Brain Abscess | 1 | 2003 | 12 | 0.060 |
Why?
| Infant, Premature | 3 | 2017 | 308 | 0.060 |
Why?
| Administration, Topical | 1 | 2003 | 54 | 0.060 |
Why?
| Fluoroscopy | 3 | 1984 | 42 | 0.060 |
Why?
| Infant, Very Low Birth Weight | 1 | 2003 | 45 | 0.060 |
Why?
| Feces | 1 | 2023 | 132 | 0.060 |
Why?
| Occupational Medicine | 1 | 1983 | 3 | 0.050 |
Why?
| Cholesterol | 1 | 2023 | 146 | 0.050 |
Why?
| Glucosamine | 1 | 1982 | 9 | 0.050 |
Why?
| Otoscopes | 1 | 2002 | 1 | 0.050 |
Why?
| Horse Diseases | 1 | 1982 | 16 | 0.050 |
Why?
| Kinetics | 1 | 2023 | 626 | 0.050 |
Why?
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 1983 | 88 | 0.050 |
Why?
| Cell Line, Tumor | 1 | 2006 | 1402 | 0.050 |
Why?
| Canada | 1 | 2002 | 98 | 0.050 |
Why?
| Nasopharynx | 1 | 2021 | 25 | 0.050 |
Why?
| Arthritis, Rheumatoid | 1 | 1982 | 105 | 0.050 |
Why?
| Viral Load | 1 | 2021 | 76 | 0.050 |
Why?
| Immunotherapy | 1 | 2003 | 238 | 0.050 |
Why?
| Radiography, Thoracic | 1 | 1981 | 66 | 0.050 |
Why?
| Nitriles | 1 | 2021 | 54 | 0.050 |
Why?
| Haemophilus influenzae | 1 | 2001 | 19 | 0.050 |
Why?
| Meningitis, Haemophilus | 1 | 2001 | 8 | 0.050 |
Why?
| Anus, Imperforate | 1 | 2000 | 8 | 0.050 |
Why?
| Adenoviridae | 1 | 2020 | 51 | 0.050 |
Why?
| Staining and Labeling | 1 | 2001 | 97 | 0.050 |
Why?
| Data Collection | 1 | 2002 | 279 | 0.050 |
Why?
| Testis | 1 | 1981 | 69 | 0.050 |
Why?
| Nose | 1 | 2000 | 31 | 0.050 |
Why?
| Ovary | 1 | 1981 | 104 | 0.050 |
Why?
| Cytokines | 1 | 2003 | 612 | 0.050 |
Why?
| Administration, Intravenous | 1 | 2020 | 68 | 0.040 |
Why?
| Host-Pathogen Interactions | 1 | 2021 | 129 | 0.040 |
Why?
| Microcephaly | 1 | 2000 | 41 | 0.040 |
Why?
| Pyridines | 1 | 2021 | 130 | 0.040 |
Why?
| Cerebellar Cortex | 1 | 1980 | 6 | 0.040 |
Why?
| Goats | 1 | 1980 | 10 | 0.040 |
Why?
| Photofluorography | 1 | 1979 | 2 | 0.040 |
Why?
| Syndrome | 1 | 2000 | 234 | 0.040 |
Why?
| Sheep | 1 | 1980 | 89 | 0.040 |
Why?
| Consensus | 1 | 2020 | 143 | 0.040 |
Why?
| Respirovirus | 1 | 2019 | 1 | 0.040 |
Why?
| Orthomyxoviridae | 1 | 2019 | 3 | 0.040 |
Why?
| Rats | 1 | 2006 | 3300 | 0.040 |
Why?
| Enterovirus | 1 | 2019 | 4 | 0.040 |
Why?
| Metapneumovirus | 1 | 2019 | 5 | 0.040 |
Why?
| Respiratory Syncytial Viruses | 1 | 2019 | 12 | 0.040 |
Why?
| Cattle | 1 | 1980 | 210 | 0.040 |
Why?
| Rhinovirus | 1 | 2019 | 23 | 0.040 |
Why?
| Coronavirus | 1 | 2019 | 16 | 0.040 |
Why?
| Antiviral Agents | 1 | 2020 | 174 | 0.040 |
Why?
| History, 21st Century | 1 | 2018 | 57 | 0.040 |
Why?
| History, 20th Century | 1 | 2018 | 100 | 0.040 |
Why?
| Disease Management | 1 | 2019 | 174 | 0.040 |
Why?
| Complex Mixtures | 1 | 2017 | 7 | 0.040 |
Why?
| K562 Cells | 1 | 2017 | 42 | 0.040 |
Why?
| Farnesol | 1 | 2017 | 4 | 0.040 |
Why?
| Proteolysis | 1 | 2017 | 94 | 0.040 |
Why?
| HeLa Cells | 1 | 2017 | 251 | 0.040 |
Why?
| Cardiovascular Diseases | 2 | 1979 | 440 | 0.030 |
Why?
| Magnetic Resonance Imaging | 1 | 2003 | 1533 | 0.030 |
Why?
| Critical Illness | 1 | 2017 | 286 | 0.030 |
Why?
| Cell Line | 1 | 2017 | 1002 | 0.030 |
Why?
| Pneumonia | 1 | 2015 | 117 | 0.030 |
Why?
| Technology, Radiologic | 3 | 1983 | 19 | 0.030 |
Why?
| Prevalence | 2 | 2009 | 943 | 0.030 |
Why?
| Gestational Age | 2 | 2004 | 417 | 0.030 |
Why?
| Evidence-Based Medicine | 1 | 2012 | 248 | 0.020 |
Why?
| Germany, East | 2 | 1988 | 3 | 0.020 |
Why?
| Cryptococcus | 1 | 2010 | 2 | 0.020 |
Why?
| Antineoplastic Agents | 1 | 2018 | 1172 | 0.020 |
Why?
| Food Microbiology | 1 | 2009 | 49 | 0.020 |
Why?
| Food | 1 | 2009 | 71 | 0.020 |
Why?
| Deoxycholic Acid | 1 | 2009 | 17 | 0.020 |
Why?
| Liver Function Tests | 1 | 2009 | 46 | 0.020 |
Why?
| North America | 1 | 2009 | 66 | 0.020 |
Why?
| Lung Neoplasms | 1 | 2015 | 605 | 0.020 |
Why?
| Drug Combinations | 1 | 2009 | 123 | 0.020 |
Why?
| Infusions, Intravenous | 1 | 2009 | 207 | 0.020 |
Why?
| Drug Administration Schedule | 1 | 2009 | 376 | 0.020 |
Why?
| Diagnosis, Differential | 2 | 2003 | 1036 | 0.020 |
Why?
| Disease Notification | 1 | 2007 | 10 | 0.020 |
Why?
| Survival Analysis | 1 | 2009 | 659 | 0.020 |
Why?
| Recurrence | 1 | 2009 | 651 | 0.020 |
Why?
| Hypercalcemia | 1 | 2007 | 33 | 0.020 |
Why?
| Ethics Committees, Research | 1 | 2006 | 15 | 0.020 |
Why?
| Leukocyte Count | 1 | 2006 | 70 | 0.020 |
Why?
| Los Angeles | 1 | 2006 | 30 | 0.020 |
Why?
| Multicenter Studies as Topic | 1 | 2006 | 84 | 0.020 |
Why?
| RNA, Fungal | 1 | 2006 | 21 | 0.020 |
Why?
| Referral and Consultation | 1 | 1988 | 287 | 0.020 |
Why?
| Guideline Adherence | 1 | 2007 | 132 | 0.020 |
Why?
| Disease Progression | 1 | 2009 | 822 | 0.020 |
Why?
| Quality of Health Care | 1 | 2007 | 185 | 0.020 |
Why?
| Research | 1 | 2006 | 112 | 0.020 |
Why?
| Decision Theory | 1 | 1985 | 2 | 0.020 |
Why?
| Statistics as Topic | 1 | 1985 | 89 | 0.020 |
Why?
| Transplantation Conditioning | 1 | 2005 | 83 | 0.020 |
Why?
| Blood | 1 | 2004 | 28 | 0.010 |
Why?
| Blood Glucose | 1 | 2006 | 432 | 0.010 |
Why?
| Meningitis | 1 | 2003 | 24 | 0.010 |
Why?
| Television | 2 | 1981 | 16 | 0.010 |
Why?
| Hypertension | 1 | 1988 | 532 | 0.010 |
Why?
| Immunophilins | 1 | 2003 | 1 | 0.010 |
Why?
| Follow-Up Studies | 1 | 1988 | 2179 | 0.010 |
Why?
| RNA, Messenger | 1 | 2006 | 1105 | 0.010 |
Why?
| Brain Diseases | 1 | 2003 | 82 | 0.010 |
Why?
| Heart Valve Prosthesis | 1 | 2004 | 75 | 0.010 |
Why?
| Sirolimus | 1 | 2003 | 62 | 0.010 |
Why?
| Horses | 1 | 1982 | 44 | 0.010 |
Why?
| Prosthesis-Related Infections | 1 | 2004 | 103 | 0.010 |
Why?
| Mediastinum | 1 | 1981 | 22 | 0.010 |
Why?
| Diaphragm | 1 | 1981 | 29 | 0.010 |
Why?
| Heart | 2 | 1981 | 326 | 0.010 |
Why?
| Purkinje Cells | 1 | 1980 | 15 | 0.010 |
Why?
| Microscopy, Electron | 1 | 1980 | 77 | 0.010 |
Why?
| Mass Chest X-Ray | 1 | 1974 | 1 | 0.010 |
Why?
| Quality Control | 1 | 1984 | 94 | 0.000 |
Why?
| Electronics, Medical | 1 | 1977 | 4 | 0.000 |
Why?
| Cardiac Volume | 1 | 1974 | 6 | 0.000 |
Why?
| Methods | 1 | 1974 | 55 | 0.000 |
Why?
| False Negative Reactions | 1 | 1974 | 29 | 0.000 |
Why?
| Physical Exertion | 1 | 1974 | 43 | 0.000 |
Why?
| Heart Ventricles | 1 | 1974 | 248 | 0.000 |
Why?
| Sex Factors | 1 | 1974 | 693 | 0.000 |
Why?
| Heart Diseases | 1 | 1974 | 208 | 0.000 |
Why?
|
|
Steinbach's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|